"Novofarm-Biosintez" LLC is expanding the product portfolio of medicinal products registered in Ukraine

“Novofarm-Biosintez” LLC is expanding the product portfolio of medicinal products registered in Ukraine 06 September 2022 To the previous page

By order of the Ministry of Health of Ukraine № 1352 of 29.07.2022, the medicinal product was registered RINGER SOLUTION, solution for infusions of 200 ml or 400 ml in bottles, 250 ml or 500 ml in bags (MA № UA/19574/01/01).

By order of the Ministry of Health of Ukraine № 1082 dated 22.06.2022, the medicinal product was registered DEXMEDETOMIDIN-NOVO, concentrate for solution for infusions, 100 μg/ml of 2 ml in vials; 5 vials in a blister; 1 blister in a cardboard pack (MA № UA/19497/01/01).

By order of the Ministry of Health of Ukraine ...

Firm “Novofarm-Biosyntez” LLC has once again successfully passed the national certification of compliance with requirements of good manufacturing practice

From 06.09.2021 to 10.09 2021, representatives of the State Service of Ukraine for Medicines and Drug Control audited the production...

Firm “Novofarm-Biosyntez” LLC expands product portfolio of medicines in the Republic of Azerbaijan

On October 11, 2021, the Company received two more registration certificates for medicines in the Republic of Azerbaijan: - Atrakurium-Novo /Atracurium-Novo...

25 years Safeguarding the Public Health

Firm "Novofarm-Biosyntez" LLC congratulates on the 25th anniversary of the Company all employees and partners who have invested their souls and hearts in its development and prosperity, thanks everyone for their work and has high hopes for the future!

Firm “Novofarm-Biosyntez” LLC continues to expand its markets

Firm "Novofarm-Biosyntez" LLC received the first registration certificate for the medicinal product Rinalipon Turbo, solution for infusion, 50 ml, in a vial No.10...

Firm “Novofarm-Biosyntez” LLC is starting a redesign of the product packaging

Spring is a time of ambitious plans, changes and new achievements. In today’s VUCA world, which is already called the era of extreme uncertainty, diversity, opportunities and motivation...